Avidity Biosciences to Present at the 2020 Wells Fargo Virtual Healthcare Conference

News provided by

Sep 03, 2020, 16:05 ET

SAN DIEGO, Sept. 3, 2020 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs^™), today announced that Sarah Boyce, Avidity's President and CEO, will participate in a fireside chat at the 2020 Wells Fargo Virtual Healthcare Conference on Thursday, September 10^th, 2020 at 9:00 am PT. The conference is being held in a virtual format.

A live webcast of the virtual fireside chat will be available on the Company's website at www.aviditybiosciences.com in the Investor Resources section. A replay of the fireside chat will be archived on the site for 60 days.

About Avidity Biosciences

Avidity Biosciences, Inc. is pioneering a new class of oligonucleotide-based therapies called AOCs designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Avidity utilizes its proprietary AOC platform to design, engineer and develop therapeutics that combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide therapies in order to access previously undruggable tissue and cell types and more effectively target underlying genetic drivers of diseases. Avidity's lead

product candidate, AOC 1001, is designed to treat myotonic dystrophy type 1, and its four other muscle programs are focused on the treatment of muscle atrophy, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy and Pompe disease. In addition to its muscle franchise, Avidity has research efforts focused on immune and other cell types.

Contacts:

Company:
Mike MacLean
(858) 401-7900
[email protected]

Media and Investors:

Amy Conrad
Juniper Point
(858) 366-3243
[email protected]

SOURCE Avidity Biosciences, Inc.